Sepsis is the most common cause of childhood death worldwide. Millions of children survive, but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly recognized as a significant factor associated with long-term mortality among different patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in the development of hypertension and cardiovascular disease. The investigators overall hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized, long-term consequences with regard to kidney function, endothelial function, blood pressure control, and overall health.

Start Date01 Oct 2019

Sponsor / Collaborator

University of Florida

[+1]

NCT02599844

/ WithdrawnNot ApplicableIIT

Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults - IMPRESS YA

Start Date01 Dec 2015

Sponsor / Collaborator

University of Florida

[+1]

100 Clinical Results associated with Iodohippurate Sodium I-131

100 Translational Medicine associated with Iodohippurate Sodium I-131

100 Patents (Medical) associated with Iodohippurate Sodium I-131

136

Literatures (Medical) associated with Iodohippurate Sodium I-131

01 Apr 2020·Annals of Nuclear Medicine

Full report on a survey of adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan

Article

Author: Yoshimura, Mana ; Matsuda, Hiroshi ; Yokoyama, Kunihiko ; Uehara, Tomoya ; Okazawa, Hidehiko ; Mizumura, Sunao

OBJECTIVEThis pharmacovigilance-based survey was aimed at determining the prevalence of, and association between, radiopharmaceuticals and adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan.METHODSThe Subcommittee for Safety Issues of Radiopharmaceuticals of the Japan Radioisotope Association's Medical Science and Pharmaceutical Committee mailed a form for reporting adverse reactions to radiopharmaceuticals to all institutes performing nuclear medicine examinations in Japan. This investigation included adverse reactions to diagnostic radiopharmaceuticals labeled with both single-photon- and positron-emitting radionuclides and therapeutic sodium iodide labeled with ¹³¹I. Each institute returned the reporting form to the subcommittee each time an adverse reaction occurred.RESULTSReplies were obtained from 75% of the institutions. In total, 1099 adverse reactions were reported from 46,645,580 radiopharmaceutical administrations, giving a prevalence of 2.4 adverse reactions per 100,000 administrations (95% confidence interval 2.2-2.5). Adverse reactions were most frequently observed for ¹³¹I-iodomethylnorcholesterol (230.1/10⁵ administrations), followed by ¹³¹I-HSA (76.3/10⁵ administrations), ¹³¹I-sodium iodohippurate (31.2/10⁵ administrations), and ^99mTc-DTPA (12.0/10⁵ administrations). Comparison of adverse reactions between before and after 1997 revealed that prevalence dropped from 3.7/10⁵ administrations (95% confidence interval 3.5-4.1) to 1.5/10⁵ administrations (95% confidence interval 1.4-1.6). During the study period, vasovagal reactions accounted for 50.3% of adverse reactions, fever for 7.5%, allergic reactions for 25.7%, and other for 16.5%; 3.7% of all adverse reactions were considered severe but none were lethal. A definite, probable, possible, less likely, and uncertain causal relationship with radiopharmaceuticals was observed in 13.1%, 33.7%, 39.9%, 6.2%, and 7.1% of adverse reactions, respectively.CONCLUSIONSThese results suggest that nuclear medicine staff must be aware of the possibility of adverse reactions from radiopharmaceuticals, despite their rarity.

01 Jan 2020·Journal of Physics: Conference Series

Stability of ¹³¹I-Ortho-Iodo-Hippuric Acid (¹³¹I-Hippuran) Labelled Compound Produced by CANST (Center of Applied Nuclear Science and Technology)-BATAN Bandung

Author: Rosyidiah, Endah ; Hafiz, Aw teguh ; Sugiharti, Rizky Juwita ; Mulyati, Titin Sri ; Sriyani, Maula Eka

Abstract131I-ortho-iodo-hippuiic acid (131-Hippuran) labelled compound has been used in nuclear medicine for renal function evaluation. The labelled compound solution administered to patients via intravenous injection. Radiation from the labelled compound tracked by gamma detector in Renograph. PSTNT has succeeded produce 131-Hippuran to cover the demand from An Nur Urology-Specialized Hospital, Yogyakarta. 131-Hippuran was purified by column chromatography method. HPLC analysis were performed to specified which fraction has higher radiochemical purity and will be used for patients. 131-Hippuran stability testing needs to be done related to the decay of radioactive compounds. Three storage temperatures were prepared as follows: 4, 25, and 30thC. Radiochemical purity of each temperature determined by paper electrophoresis method on day 1, 6, 9, 13, 20, 23, and 30. The static phase used was whatman 1 paper, while mobile phase was phosphate buffer pH 9. The initial radiochemical purity is 99.52%. While on 30” day, radiochemical purity in storage temperatures of 4, 25, and 30°C are 97.04, 96.37, and 96.96% respectively. Statistical analysis using SPSS was performed to determine whether there was a significant difference in the radiochemical purity of each storage temperature. Normality and homogeneity test showed the radiochemical purity is normally distributed and has homogenous variance at three different storage temperature. Furthermore, the result of One-way ANOVA test showed that there was no significant difference of radiochemical purity in various storage temperatures. In conclusion, 131-Hippuran labelled compound produced by CANST-BATAN Bandung is relatively stable up to 30 days and not affected by storage temperature.

01 Jan 2018·IOP Conference Series: Materials Science and Engineering

The use of Whatman-31ET paper for an efficient method for radiochemical purity test of¹³¹I-Hippuran

Author: Gunawan, Adang Hardi ; Putra, Amal Rezka ; Awaludin, Rohadi ; Chairuman ; Sugiharto, Yono ; Maskur

Current chromatog. methods used for radiochem. purity test of 131I-Hippuran is time consuming.Therefore, in this study we explored several static and mobile phases in order to have a chromatog. method which is accurate and efficient or less time consuming.In this study, stationary phases (Whatman-1, 31ET, and 3MM papers) and several mobile phases were explored to sep. 131I-Hippuran from its impurity (131I-).The results of this study showed that the most efficient chromatog. system for measurement of radiochem. purity of 131I-Hippuran was by using Whatman-31ET paper and n-butanol: acetic acid: water (4:1:1) as a static phase and mobile phase resp.Developing time for this method was of approx. 75.7 ± 2.7 min.The result of radiochem. purity (%RCP) of 131I-Hippuran measured with this chromatog. system either using Whatman-1 or Whatman-31ET paper strips was 98.7%.The short size of Whatman-31ET paper strip (1 × 8 cm) was found to have shorter developing time compared to that of long size paper.This system showed a good separation of 131I-Hippuran from its impurities and gave %RCP of 98.1% ± 0.04% with developing time approx. 44.3 ± 9.4 min.The short size of Whatman-31ET paper strips was found to be more efficient compared to that of Whatman-1 and Whatman-3MM paper strips in term of developing time.

100 Deals associated with Iodohippurate Sodium I-131

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09CX02	DB09382

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis